Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.

The PROSit cohort of infliximab biosimilar in IBD : a prolonged follow-up on the effectiveness and safety across Italy / A. Armuzzi, G. Fiorino, A. Variola, N. Manetti, W. Fries, A. Orlando, G. Maconi, F. Bossa, M. Cappello, L. Biancone, L. Cantoro, F. Costa, R. D'Incà, P. Lionetti, M. Principi, F. Castiglione, M.L. Annunziata, A. Di Sabatino, M. Di Girolamo, M.M. Terpin, C.C. Cortelezzi, S. Saibeni, A. Amato, S. Ardizzone, L. Guidi, S. Danese, A. Massella, A. Ventra, G. Rizzuto, A. Massari, F. Perri, V. Annese, S. Saettone, R. Tari, C. Petruzzellis, G. Meucci, G. Imperiali, F.W. Guglielmi, S. Mazzuoli, L. Caserta, M.C. Parodi, A. Colli, A. Ronchetti, D. Pugliese, A. Geccherle, F. Rogai, S. Milani, S. Renna, A. Cassinotti, A. Andriulli, G. Martino, B. Scrivo, E. Troncone, A. Kohn, L. Bertani, G. Lorenzon, S. Ghione, O. Nardone, M. Vecchi, A. Bertani, M.A. Bosani, C. Bezzio, R. Salerno. - In: INFLAMMATORY BOWEL DISEASES. - ISSN 1078-0998. - 25:3(2019 Feb), pp. 568-579.

The PROSit cohort of infliximab biosimilar in IBD : a prolonged follow-up on the effectiveness and safety across Italy

G. Maconi;S. Saibeni;S. Ardizzone;A. Massari;S. Milani;A. Cassinotti;M. Vecchi;M.A. Bosani;C. Bezzio;
2019-02

Abstract

Background: We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. Methods: A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. Results: Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naïve to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One hundred fifty-four SAEs were reported (19%), leading to cessation of the biosimilar in 103 subjects (12.7%). Infusion reactions were 71, leading to cessation of the biosimilar in 53 subjects (6.5%), being significantly more frequent in patients pre-exposed to anti-TNFα (P = 0.017). The efficacy of therapy was calculated in 754 IBD patients, with a mean follow-up of 329 ± 202 days. Forty-eight patients had a primary failure (6.4%), and 188 (25.6%) lost response during follow-up. Six hundred twenty-eight (364 CD) and 360 IBD patients (222 CD) completed the follow-up at 6 and 12 months, respectively. At 12 months, patients without loss of response were 71%, 64%. and 82% in groups A, B, and C, respectively (log rank P = 0.01). Clinical/endoscopic scores and inflammatory biomarkers dropped significantly in CD and UC patients (P = 0.01 and P < 0.0001) compared with baseline. Conclusions: In this large prospective cohort, no further signals of difference in safety and effectiveness of CT-P13 in IBD has been observed.
Biosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Immunology and Allergy; Gastroenterology
Settore MED/12 - Gastroenterologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
izy264.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/641136
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 40
social impact